Liana K Billings Selected Research

IDegLira

1/2021	The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
1/2020	IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
1/2020	Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
12/2019	IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
1/2019	Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
4/2018	An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
1/2018	Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liana K Billings Research Topics

Disease

20	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2010
7	Body Weight (Weight, Body) 01/2022 - 01/2018
6	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2015
5	Weight Loss (Weight Reduction) 01/2021 - 01/2018
3	Weight Gain 01/2021 - 01/2018
3	Insulin Resistance 03/2014 - 03/2013
2	Obesity 01/2021 - 03/2013
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2021
1	Diabetes Complications 12/2021
1	Infections 06/2021
1	COVID-19 06/2021
1	Sickle Cell Trait 06/2021
1	Body Weight Changes 01/2021
1	Overweight 01/2021
1	Nausea 01/2019
1	Hyperglycemia 09/2018
1	Stroke (Strokes) 09/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2018
1	Hypertension (High Blood Pressure) 09/2014

Drug/Important Bio-Agent (IBA)

11	Insulin (Novolin)FDA Link 01/2022 - 08/2012
8	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 08/2012
7	IDegLiraIBA 01/2021 - 01/2018
6	Blood Glucose (Blood Sugar)IBA 12/2021 - 01/2018
6	Insulin Glargine (Lantus)FDA Link 11/2021 - 01/2018
5	insulin degludecIBA 11/2021 - 04/2018
5	Metformin (Glucophage)FDA LinkGeneric 12/2019 - 12/2013
4	Liraglutide FDA Link 01/2021 - 04/2018
2	semaglutideIBA 01/2021 - 09/2018
2	Glipizide (Glucotrol)FDA LinkGeneric 01/2015 - 12/2013
2	hydroxide ionIBA 09/2014 - 03/2013
2	Vitamin D FDA LinkGeneric 09/2014 - 03/2013
2	25-hydroxyvitamin DIBA 09/2014 - 03/2013
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 06/2021
1	SodiumIBA 01/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019
1	Lipase (Acid Lipase)FDA Link 01/2019
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 09/2018
1	Pharmaceutical PreparationsIBA 09/2018
1	Glucagon-Like Peptide 1 (GLP 1)IBA 09/2018
1	omega-Chloroacetophenone (Mace)IBA 09/2018
1	lixisenatideIBA 04/2018
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2018
1	DiamondIBA 01/2018
1	Insulin Aspart (NovoLog)FDA Link 01/2018
1	SugarsIBA 01/2015
1	zinc-binding protein (zinc binding protein)IBA 05/2014
1	Triglycerides (Triacylglycerol)IBA 03/2014
1	Aromatic Amino Acids (Aromatic Amino Acid)IBA 12/2013

Therapy/Procedure

11	Therapeutics 01/2022 - 12/2013
2	Drug Therapy (Chemotherapy) 01/2021 - 11/2010
2	Glycemic Control 01/2020 - 09/2018
2	Injections 12/2019 - 01/2018
1	Caloric Restriction 01/2021